MBEC Versus MBIC: the Lack of Differentiation between Biofilm Reducing and Inhibitory Effects as a Current Problem in Biofilm Methodology
Tóm tắt
Biofilms are communities of aggregated, matrix-embedded microbial cells showing a high tolerance to an in principle adequate antibiotic therapy, often resulting in treatment failure. A major challenge in the management of biofilm-associated infections is the development of adequate, standardized biofilm susceptibility testing assays that are clinically meaningful, i.e. that their results correlate with treatment outcome. Different biofilm susceptibility endpoint parameters like the minimal biofilm eradication concentration (MBEC) or the minimal biofilm inhibitory concentration (MBIC) have been suggested as a guide for treatment of biofilm-associated infections, however with inconsistent perception and use among biofilm researchers, leading to confusion and contradictions among different anti-biofilm component studies and clinical trials.
Evaluation of anti-biofilm effects is mostly based on the untreated reference growth control biofilm measured at the same endpoint as the treated biofilm, neglecting the possible change of the untreated reference biofilm from the time point of pre-antimicrobial exposure to the measured endpoint. In this commentary, we point out the importance of individual quantification of mature, established biofilms before antimicrobial treatment for each biofilm model in order to draw conclusions on the measured biofilm effect size, i.e. biofilm reducing (MBEC) or biofilm inhibitory (MBIC) effects.
The assessment of pre-treatment biofilms contributes to a standardized use of biofilm susceptibility endpoint parameters, which is urgently needed to improve the clinical validity of future anti-biofilm assays.
Từ khóa
Tài liệu tham khảo
Bjarnsholt T, Alhede M, Alhede M, Eickhardt-Sorensen SR, Moser C, Kuhl M, et al. The in vivo biofilm. Trends Microbiol. 2013;21(9):466–74.
Macia MD, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infect. 2014;20(10):981–90.
Azeredo J, Azevedo NF, Briandet R, Cerca N, Coenye T, Costa AR, et al. Critical review on biofilm methods. Crit Rev Microbiol. 2017;43(3):313–51.
Wiegand C, Volpel A, Ewald A, Remesch M, Kuever J, Bauer J, et al. Critical physiological factors influencing the outcome of antimicrobial testing according to ISO 22196 / JIS Z 2801. PLoS One. 2018;13(3):e0194339.
Coenye T, Goeres D, Van Bambeke F, Bjarnsholt T. Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? Clin Microbiol Infect. 2018;24(6):570–2.
Magana M, Sereti C, Ioannidis A, Mitchell CA, Ball AR, Magiorkinis E, et al. Options and limitations in clinical investigation of bacterial biofilms. Clin Microbiol Rev. 2018;31(3). https://doi.org/10.1128/CMR.00084-16 .
Dall GF, Tsang SJ, Gwynne PJ, MacKenzie SP, Simpson A, Breusch SJ, et al. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. J Antimicrob Chemother. 2018;73(7):1830–40.
Cruz CD, Shah S, Tammela P. Defining conditions for biofilm inhibition and eradication assays for gram-positive clinical reference strains. BMC Microbiol. 2018;18(1):173.
Brady AJ, Laverty G, Gilpin DF, Kearney P, Tunney M. Antibiotic susceptibility of planktonic- and biofilm-grown staphylococci isolated from implant-associated infections: should MBEC and nature of biofilm formation replace MIC? J Med Microbiol. 2017;66(4):461–9.
Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol. 2011;46(2):184–92.
Sandoe JA, Wysome J, West AP, Heritage J, Wilcox MH. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother. 2006;57(4):767–70.
Yau YC, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. J Cyst Fibros. 2015;14(2):262–6.
http://www.innovotech.ca/wp-content/uploads/2019/02/MBEC-Procedural-Manual-v2.0.pdf . Accessed 21 May 2019.